Recombinant Lloviu virus as a tool to study viral replication and host responses

Next generation sequencing has revealed the presence of numerous RNA viruses in animal reservoir hosts, including many closely related to known human pathogens. Despite their zoonotic potential, most of these viruses remain understudied due to not yet being cultured. While reverse genetic systems can facilitate virus rescue, this is often hindered by missing viral genome ends. A prime example is Lloviu virus (LLOV), an uncultured filovirus that is closely related to the highly pathogenic Ebola virus. Using minigenome systems, we complemented the missing LLOV genomic ends and identified cis-acting elements required for LLOV replication that were lacking in the published sequence. We leveraged these data to generate recombinant full-length LLOV clones and rescue infectious virus. Similar to other filoviruses, recombinant LLOV (rLLOV) forms filamentous virions and induces the formation of characteristic inclusions in the cytoplasm of the infected cells, as shown by electron microscopy. Known target cells of Ebola virus, including macrophages and hepatocytes, are permissive to rLLOV infection, suggesting that humans could be potential hosts. However, inflammatory responses in human macrophages, a hallmark of Ebola virus disease, are not induced by rLLOV. Additional tropism testing identified pneumocytes as capable of robust rLLOV and Ebola virus infection. We also used rLLOV to test antivirals targeting multiple facets of the replication cycle. Rescue of uncultured viruses of pathogenic concern represents a valuable tool in our arsenal for pandemic preparedness.


Introduction
Zoonotic viruses are a major public health threat. A single spillover event from an animal host into the human population can initiate deadly epidemics or even pandemics. Bats play an important role as natural reservoirs of RNA viruses with the potential to cause significant harm to humans. Examples of bat-borne viruses that have been transmitted to humans, either directly or via intermediate hosts, causing multiple epidemics include Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Hendra virus, Nipah virus, and Marburg virus (MARV). For other viruses, such as Middle East Respiratory Syndrome coronavirus (MERS-CoV), pandemic SARS-CoV-2, and Ebola virus (EBOV), there is strong evidence that bats might be the natural reservoir, although these viruses have not yet been isolated from bats [1]. While some of these represent reemerging viruses that were already known to cause severe disease in humans, this list also includes a number of bat-borne viruses that were either unknown or understudied prior to spillover into the human population.
To better prepare for potential future zoonotic epidemics and pandemics, it is necessary to study newly discovered viruses that are closely related to highly pathogenic viruses to both determine their pathogenic potential and to develop and assess potential antiviral therapies. Since 2000, multiple new filoviruses have been discovered via next generation sequencing of samples from wild bats across the globe, including Lloviu virus (LLOV), Bombali virus, and Mengla virus [2][3][4], but the ability to study these viruses has been limited because none of these new viruses have been cultured to date.
One particular virus of concern is LLOV, a filovirus whose viral RNA was initially isolated from carcasses of Schreiber's bats (Miniopterus schreibersii) in Spain and France using deep sequencing and PCR techniques and later found in the same species of bats in Hungary, although no infectious virus has been cultured to date [2,5,6]. Recently, LLOV re-emerged in bat populations in Northeast Hungary, and again its emergence correlated with unexplained increased mortality among Schreiber's bats [5]. Interestingly, many of the bats in which LLOV RNA was found showed symptoms of respiratory infection, but it remains to be determined if LLOV is the causative agent of the disease [2,5]. One worrying factor regarding the spillover potential for LLOV is the geographic range of the host species, Miniopterus schreibersii, which can be found across most of southern Europe, parts of northern Africa, and much of the Middle East, in which over 100 million people live. At the sequence level, LLOV is distinct enough from the ebola-and marburgviruses to be classified within its own genus Cuevavirus [7]. Although the pathogenic potential of LLOV remains unknown, similarities to EBOV and MARV raise concerns that it could be pathogenic for humans. However, the pathogenicity of filoviruses varies considerably, highlighting the need to study LLOV in more detail.
Like many of the genomic sequences of these other uncultured RNA viruses, the LLOV genome is incomplete [2]. The lack of the terminal genomic sequences that orchestrate viral transcription and replication makes development of a fully wild-type reverse genetic system to rescue the virus impossible. Here we describe the complementation of the LLOV sequence with terminal genomic sequences from other filoviruses in mono-and bicistronic minigenome systems to determine the ability of these sequences to facilitate different aspects of the LLOV replication cycle. Leveraging the data from these complementation assays, we were able to develop a reverse genetic system that facilitated the rescue of infectious recombinant Lloviu virus complemented with sequences from EBOV or MARV (rLLOV comp ). We analyzed rLLOV comp in various assays, ranging from ultrastructural analysis of infected cells to infection studies with primary human cells, antiviral testing, and host response analysis. Our data suggest that LLOV has the potential to infect humans but does not induce an inflammatory response in human macrophages, a hallmark of severe Ebola virus disease [8]. The success of this approach provides a roadmap for the rescue and characterization of other uncultured RNA viruses of pathogenic concern for which we currently only have incomplete genomic sequences.

Results and discussion
Complementation assays to identify functional 5 0 genomic ends for LLOV As a member of the filovirus family, LLOV has a nonsegmented negative sense RNA genome. The published LLOV genome sequence lacks four 3 0 terminal nucleotides and almost the entire trailer region. Since the replication and transcription promoter regions of negative sense RNA viruses are contained within the genome ends, called the leader and trailer regions, the lack of the terminal sequences has hampered the generation of recombinant LLOV clones and viral rescue. We previously showed that chimeric LLOV minigenomes that utilize the LLOV leader complemented with four 3 0 terminal EBOV nucleotides in combination with the polymerase (L) gene 5 0 noncoding region (encoding the 3 0 UTR of the L mRNA) and trailer regions ( UTR+tr ) of EBOV, RESTV, and MARV are each replication and transcription competent [9]. To identify a potent chimeric trailer region for use in full-length rLLOV comp clones, we generated LLOV minigenomes containing the complete LLOV 5 0 noncoding region including the sequence encoding the L 3 0 UTR and the 8 known nucleotides of the LLOV trailer complemented with varying lengths of 5 0 terminal sequences of the EBOV Mayinga genome (Fig 1A). Minigenomes with these chimeric LLOV-EBOV 5 0 ends were functional, with a general trend of the shorter hybrid trailers being less active (Figs 1B and S1). Of note, some of these LLOV minigenomes with chimeric trailers were more active than the LLOV minigenome utilizing the full 5 0 end of EBOV (EBOV UTR+tr , Figs 1B and S1). chosen because this minigenome performed best in the minigenome assay (Figs 1B and S1). Since there are no commercially available antibodies against LLOV and we detected no crossreactivity with LLOV proteins using antibodies against other filoviruses, we also constructed these rLLOV comp full-length clones with the addition of a ZsGreen reporter attached to the VP40 gene via a P2A sequence as previously described for EBOV [10]. Viral rescue was attempted by transfecting cocultures of African green monkey kidney (Vero E6) and human hepatocarcinoma (Huh7) cells with full-length clone rLLOV comp plasmids along with codonoptimized LLOV support plasmids as previously described for the LLOV minigenome system [9]. However, repeated attempts to rescue these clones were unsuccessful (S2 Fig). One striking observation regarding the published LLOV genomic sequence is the lack of gene end (GE) and gene start (GS) signals within the VP24-L intergenic region (IR), which has led to speculation that these genes may be expressed bicistronically [2]. However, this would be unique, as there are, to our knowledge, no instances of bicistronic or polycistronic genes for any nonsegmented negative sense RNA viruses outside of the bornavirus family [11,12]. To test whether this lack of GE and GS signals might play a role in the expression of both the LLOV VP24 and L genes, we constructed and tested a bicistronic minigenome that included the wild-type VP24-L IR between firefly and renilla luciferase reporter genes ( Fig 1C). Although we saw expression of the first reporter gene in a minigenome assay, expression of the second gene was not observed (Fig 1D). The addition of conserved LLOV GE and GS signals within this IR in the bicistronic minigenome (IR ins ), however, facilitated efficient expression of both reporter genes, indicating that there is a strict requirement for flanking GS and GE signals for each LLOV gene (Fig 1D).

Rescue and characterization of recombinant Lloviu viruses
Incorporation of the VP24-L IR ins sequence into rLLOV comp full-length genomes facilitated the rescue of three different versions of rLLOV comp containing the ZsGreen-P2A-VP40 Schematic of LLOV minigenomes with EBOV noncoding region (negative sense L gene 3ˈ UTR) and trailer (top) or hybrid 5ˈ genome ends consisting of the LLOV L gene 3ˈ UTR and trailer complemented with short terminal sequences from the EBOV trailer, designated LE X where X represents the number of added terminal nucleotides from EBOV. Le, leader; NP, nucleoprotein; L, polymerase; Tr, trailer. (B) Luciferase-based minigenome assays comparing the 3L5E [9] and chimeric 3L5LE X minigenomes. Mean fold induction of firefly luciferase activity over the negative control (minus L) and normalized to ß-galactosidase activity (transfection control) with standard deviation is shown. (C) Schematic of bicistronic 3L5LE 72 minigenomes containing firefly and renilla luciferase reporters separated by either the wild-type LLOV VP24-L intergenic region (IR wt ) or the same intergenic region with an inserted gene border (IR ins ) consisting of overlapping LLOV gene end (GE, red bar) and gene start (GS, green triangle) signals. (D) Luciferase-based minigenome assays comparing the bicistronic minigenomes. Mean fold induction of firefly and renilla luciferase activities over the negative controls (minus L) and normalized to ß-galactosidase activity (transfection control) with standard deviation is shown. https://doi.org/10.1371/journal.ppat.1010268.g001

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses reporter, EBOV UTR+tr , MARV UTR+tr , and LE 72 (Figs 2A and S2). The ability of these viruses to be rescued only with the addition of the IR ins sequence further highlights the strict functional need for GS and GE sequences within the LLOV genome. This raises questions about whether the published LLOV VP24-L IR sequence is potentially incomplete, possibly due to masking of IR sequences on the viral genome by abundant viral mRNA or due to possible sequencing difficulty caused by RNA secondary structures. However, since the sequencing files from the original discovery of LLOV are not publicly available, these hypotheses cannot be assessed [2].
We next sought to compare replication kinetics of rescued Lloviu viruses with recombinant EBOV (Mayinga) and RESTV (Pennsylvania) containing ZsGreen-P2A-VP40 reporters in three different cell lines. All three rLloviu viruses grew to lower titers in Vero E6 cells, a cell line frequently used for filovirus replication kinetics, and replicated more slowly than both the rEBOV and rRESTV, with rLLOV-LE 72 representing the slowest-growing virus (Fig 2B). Similar patterns of growth kinetics were observed in Huh7 cells and in the bat (M. schreibersii) kidney cell line SuBK12-08 [13] using two different initial multiplicities of infection (MOIs), with the notable exception that rRESTV grew comparatively slower in the bat cells (Figs 2C, 2D and S3). While Vero E6 and SuBK12-08 cells can be kept in culture without passaging for up to two weeks without showing cytopathic effects, Huh7 cells require passaging after 4-5 days, explaining the shorter incubation period for the Huh7 cells in this experiment. Proteomic analysis of SuBK12-08 cells infected with rLLOV comp revealed abundant levels of LLOV proteins, with a trend of viral proteins encoded closer to the 3 0 genomic terminus producing higher relative signal intensities, indicative of greater abundance (Figs 2E and S4). This mirrors

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses the transcriptional gradients observed in EBOV and MARV infections [14]. The published LLOV sequence contains a hypothetical open reading frame predicted to be encoded on the antigenome overlapping the VP24 gene (rcORF, GenBank: JF828358.1, "hypothetical protein", complement(10572..11141)). However, there are no GS or GE signals flanking this ORF and there are no published reports of any filoviruses having the ability to transcribe from the antigenome. Proteomic analysis did not indicate any evidence for the expression of this rcORF.
Vero E6 cells infected with rLLOV comp showed typical filoviral inclusions by RNA fluorescence in situ hybridization (FISH) analysis, as visualized by clustered localization of viral genomic RNA (Fig 2F). Similarly, infection of both human (Huh7) and bat (SuBK12-08) cells with rLLOV comp showed characteristic filovirus inclusions by ultrastructural analysis, with both transverse and longitudinal sections of filamentous nucleocapsids visualized by electron microscopy (EM), similar to filovirus inclusions [15]

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses terminal sequences of either of these viruses. These changes were all detected at low abundance despite good sequencing coverage, with the exception of an untemplated AC dinucleotide at the 5 0 terminal end of the rLLOV-EBOV UTR+tr sequence found in about 20% of sequence reads ( S7 Fig and S1 Dataset). The relative lack of mutations at the 5 0 end of these viruses indicates that the LLOV polymerase has some flexibility in promoter recognition.
To gain insight into LLOV host cell tropism, we compared the ability of rLLOV comp and rEBOV to infect two key target cell types during filovirus infections in humans, macrophages and hepatocytes [17]. Both monocyte-derived macrophages (MDMs) and induced pluripotent stem cell (iPSC)-derived, primary-like hepatocytes (iHeps) [18] were permissive to infection with rLLOVcomp and rEBOV (Fig 4A and 4B). These data indicate that there is no species or cell-type tropism block that would prevent LLOV from being able to productively infect human cells.
Since some of the Schreiber's bats identified during LLOV-associated die-offs showed lung infiltrates [2,5], we also tested the ability of these viruses to infect iPSC-derived human alveolar type 2 cells (iAT2s) [19,20], an important lung cell type which had never been previously analyzed in the context of filovirus infections. Both rEBOV and rLLOV comp were able to infect these cells efficiently, with rapid virus spread ( Fig 4C). Although filovirus infections in humans have not been associated with aerosol spread, the lung is a target organ of EBOV infection in humans as shown by pulmonary histopathology of fatal EBOV disease cases [17]. In addition, EBOV infection through the aerosol route has been demonstrated in nonhuman primates [21]. EBOV and RESTV infections of pigs were associated with lung pathology and oronasal shedding of viral particles [22,23], indicating that there might be host and virus species specific differences in filoviral pathogenesis and transmission routes.

Use of rLLOV comp to test the efficacy of potential therapeutics
One highly useful application for recombinant viruses such as rLLOV comp that are rescued with the aid of complementation with small non-coding terminal sequences from closely related viruses is the ability to study the effects of antiviral compounds on a highly authentic replication-competent virus. Comparing rLLOV comp and rEBOV in both human and bat cells, we found similar inhibition of each virus in both cell types by remdesivir (Figs 5A and S8), a

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses nucleoside analog known to inhibit EBOV RNA synthesis [24], confirming recently published results using a LLOV minigenome system [25]. Parallel analysis using U18666A, an inhibitor of the filovirus receptor Niemann-Pick C1 (NPC1) previously shown to inhibit EBOV entry [26,27], also showed inhibition of both viruses in both cell types (Figs 5B and S8), which is in line with previous results indicating that LLOV uses NPC1 to mediate cell entry [28]. rLLOV comp was slightly more sensitive to universal type I IFN pre-treatment than rEBOV, particularly in human cells (Figs 5C and S8). Conversely, while mAb114 (brand name Ebanga), a neutralizing monoclonal antibody targeting EBOV GP and approved for treatment of EBOV disease [29], effectively blocked rEBOV infection in a dose-dependent manner at concentrations similar to those previously published [29], it had no effect on rLLOV comp replication (Fig 5D and S8). This corroborates previous studies showing that pan-ebolavirus anti-GP antibodies did not block entry of vesicular stomatitis virus pseudotyped with LLOV GP [30], emphasizing the requirement of designing antivirals tailored to the virus of interest. In summary, rLLOV comp can be used to test all steps of the viral replication cycle, including entry, viral RNA synthesis, assembly, and egress, as potential targets for antiviral therapeutics using a single system.

Use of rLLOV comp for host response analysis
A hallmark of severe EBOV infection is an exacerbated inflammatory response characterized by the induction of interferon-stimulated genes and proinflammatory modulators [8]. This inflammatory response is likely driven by activated monocytes and macrophages [31]. We previously compared the host response to infection with the highly pathogenic EBOV and the less pathogenic RESTV in human MDMs and observed a strong upregulation of type I IFN and proinflammatory responses in EBOV-infected MDMs, whereas RESTV-infected MDMs remained mainly silent [32]. To explore whether rLLOV comp would induce an EBOV-or RESTV-like host response in macrophages, MDMs obtained from 3 donors were infected with EBOV, RESTV, or rLLOV comp at an MOI of 10. RNA-FISH analysis demonstrated the presence of viral genome and transcripts for all viruses with minimal background staining observed in mock-infected cells (Figs 6A and S9), yet variable infection rates were observed, with a trend of rLLOV comp having infection rates similar to, or higher than, EBOV and RESTV. However, rLLOV comp infections generally appeared to be in an earlier stage of infection as evidenced by less abundant positive and negative sense viral RNA (Figs 6A and S10). Infection rates also varied between donors ( Fig  6A). Typical filoviral inclusions within the cytoplasm of the infected MDMs were observed for all

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses viruses as visualized by viral RNA clusters, particularly with viral genomic RNA, indicating robust viral replication in these cells (Fig 6B).
Transcriptional analysis of select genes confirmed previously observed responses to EBOV and RESTV infection [32]. While we observed robust upregulation of CXCL10 and IFNβ and, to a lesser extent, upregulation of IL6 and IL8 in EBOV-infected cells, there was only modest or no upregulation of the target genes in RESTV-and rLLOV comp -infected cells, suggesting that similar to RESTV, rLLOV comp does not activate human MDMs (Fig 6C).
Unstudied zoonotic viruses, particularly those closely related to known human pathogens, pose a threat of spillover with the potential to cause epidemics and pandemics within the human population. While many such RNA viruses, including filoviruses, have recently been discovered by unbiased sequencing technologies such as RNA-Seq [2][3][4], the coverage of their genomes is typically incomplete due to missing genomic terminal sequences. Here we provide a blueprint for studying uncultured, potentially pathogenic viruses that currently only exist as incomplete sequences using LLOV, a filovirus, as an example. We used noncoding terminal sequences from other filoviruses to complement the missing LLOV sequence and we also discovered that an intergenic region lacking conserved gene start and gene end signals was nonfunctional. We leveraged the data from these complementation assays to rescue recombinant LLOV. Using rLLOV comp , we show that there are no restrictions for LLOV infection of human cells, including primary targets of pathogenic filovirus infections such as macrophages and hepatocytes [17,33], seemingly indicating that spillover of LLOV to humans may be possible. While the molecular mechanisms of filovirus pathogenicity still remain elusive, previous

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses studies have hypothesized that slower replication kinetics and muted inflammatory responses with RESTV play a role in the virus being likely nonpathogenic to humans [32,34,35]. Similarly, LLOV replicates slowly and does not activate MDMs, potentially pointing to LLOV not being pathogenic in humans. Therefore, based on our data with rLLOV comp , it appears that LLOV may have a RESTV-like phenotype, having the capacity to infect humans but lacking the ability to cause disease [36].
Particularly when trying to answer questions regarding potential pathogenicity, recombinant viruses overcome limitations of other tools that analyze only isolated steps of viral replication, such as viral genome replication and transcription (minigenome assays) or viral entry (virus-like particles) [37]. Recombinant viruses allow for a plethora of studies to address questions of potential spillover and pathogenicity, including tropism studies, analyzing host responses of primary target cells, and ultimately animal infection studies. Additionally, recombinant viruses are perfectly suited to high throughput drug screens, since they are cheaper, more scalable, and subject to fewer confounding factors such as transfection efficiency that are associated with model systems. The addition of reporter genes and use of RNA-based detection assays are also particularly beneficial for this and other purposes since reagents such as antibodies to detect these novel viruses may not be available.
One limitation to using recombinant viruses with complemented genomic termini is that these exogenous sequences could be suboptimal, making these viruses replicate more slowly and to lower titers. It was therefore surprising that we did not observe substantial sequence changes within the trailer region in the rLLOV comp stocks, suggesting some flexibility of the viral polymerase complex in recognizing promoter elements.

Biosafety statement
All work with wildtype and recombinant EBOV, RESTV, and LLOV was performed in the biosafety level 4 (BSL-4) facility of Boston University's National Emerging Infectious Diseases Laboratories (NEIDL) following approved standard operating procedures in compliance with local and national regulations pertaining to handling BSL-4 pathogens and Select Agents.

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses using Ficoll separation (GE Healthcare) and isolation of CD14+ monocytes by magnetic bead selection (Milteny Biotech). CD14-selected cells were seeded into ultra-low attachment 6-well plates (Corning) for differentiation into MDMs using RPMI medium supplemented with penicillin (50 units/ml), streptomycin (50 mg/ml), HEPES (10 mM), 5% FBS (certified One Shot, Gibco) supplemented with 100 ng/mL human GMCSF (Peprotech) for 6-8 days. Differentiated MDMs were lifted from plates using Cell Stripper (Corning), and 2x10 5 cells were seeded into 24-well culture plates or 5x10 4 cells into Lab-Tek II 8-well chamber slides (Nunc/Thermo Fisher). To account for donor variations, experiments were performed with cells obtained from at least three different donors as noted in the figure legends. Throughout the figures, each donor is represented by a donor-specific symbol.

Induced pluripotent stem cell (iPSC) culture and directed differentiation into hepatocytes
The human induced pluripotent stem cell (iPSC) line "BU3" was maintained as described previously [38]. Briefly, the iPSC line was maintained in feeder free conditions on Matrigel (Corning) coated wells in mTeSR-1 media (StemCell Technologies) supplemented with 100 μg/mL Primocin. BU3 was confirmed as mycoplasma free by PCR analysis of gDNA using the following mycoplasma specific primers: 5 0 CTT CWT CGA CTT YCA GAC CCA AGG CAT 3 0 and 5 0 ACA CCA TGG GAG YTG GTA AT 3' and verified as karyotypically normal as determined by Gband karyotyping analysis from 20 metaphases. iPSC directed differentiation towards the hepatic lineage was performed using a previously published protocol [18,39,40]. Briefly, undifferentiated iPSCs were cultured until confluent and then passaged on Day 0 using gentle cell dissociation reagent (GCDR, StemCell Technologies) to achieve single cell suspensions and replated at 1x10 6 cells per well of a Matrigel coated 6-well plate. Cells were then placed into hypoxic conditions for the remainder of the protocol (5% O2, 5% CO2, 90% N2). Post-passage cells were patterned using the STEMdiff definitive endoderm kit (StemCell Technologies) for 5 days. Day 1 cells were grown in basal media supplemented with STEMdiff Definitive Endoderm Supplements MR and CJ followed by an additional 3 days (Days 2-4) in basal media supplemented with CJ alone. At day 5, endoderm was then passaged with GCDR at a 1:4 ratio onto Matrigel-coated wells and cultured in base complete serum-free differentiation medium (cSFDM) supplemented with growth factors as previously described [18,39,40]. Cells were then cultured for at least an additional 17 days using stage specific growth factors to specify the hepatic lineage and induce maturation.

Generation of iAT2 air-liquid interface (ALI) culture
The human iPSC line, SPC2-ST-B2, engineered to carry a tdTomato reporter targeted to the endogenous SFTPC locus [19], underwent directed differentiation to generate iPSC-derived alveolar epithelial type 2 cells (iAT2s) in 3D Matrigel cultures using methods we have previously published [41,42]. Briefly, to establish pure cultures of iAT2s, cells were sorted by flow cytometry to isolate SFTPCtdTomato+ cells on day 41 of differentiation, and subsequently maintained through serial passaging as self-renewing monolayered epithelial spheres by plating in Matrigel (Corning) droplets at a density of 400 cells/μl. The cultures were fed every other day with a defined serum-free distal lung maintenance media composed of base cSFDM supplemented with 3 μM CHIR99021, 10 ng/mL KGF, 50 nM dexamethasone, 0.1 mM cAMP, and 0.1 mM IBMX, referred to as "CK+DCI" media and as described previously [42]. iAT2 culture quality and purity were monitored at each passage by flow cytometry, where > 80% of cells expressing SFTPCtdTomato was observed over time, as shown previously [19,42].

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses hESC-Qualified Matrigel (Corning) in CK+DCI with 10 μM Rho-associated kinase inhibitor (Sigma Y-27632). At 48h after plating, apical medium is aspirated to initiate air-liquid interface culture, and cultures were fed with CK+DCI basolateral medium every other day prior to experiments.

Viral sequences
The following NCBI reference filovirus sequences were used for cloning where indicated and for sequence comparison:

Cloning of for hybrid trailer minigenomes
LLOV minigenomes containing hybrid LLOV L 3 0 untranslated region (UTR) and trailer appended with sequences from the EBOV trailer were created as follows. A DNA fragment containing the LLOV L 3 0 UTR and trailer (nucleotides 18821-18927) appended with the full EBOV L 3 0 UTR and trailer (nucleotides 18220-18959) was synthesized (Twist Biosciences) and inserted into the minigenome plasmid 3L5E-Luc [9] via NotI and XmaI digestion and ligation (3L5LE full -Luc). Truncated versions containing the LLOV L 3 0 UTR and trailer appended with the last 48 to 84 nucleotides of the EBOV trailer ( Fig 1A) were generated using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs).

Cloning of bicistronic minigenomes
A LLOV bicistronic minigenome was generated by cloning a synthesized fragment (Twist Biosciences) containing a short fragment of the LLOV 5 0 UTR of the nucleoprotein (NP) gene and 3 0 UTR of the polymerase (L) gene flanking firefly and renilla luciferase reporters separated by the VP24-L intergenic region (IR) of LLOV (nucleotides 11866-12229, IR wt ) into minigenome plasmid 3L5LE 72 -Luc using EcoRI and SpeI sites. The IR ins version of the LLOV bicistronic minigenome was generated by replacing the wild-type VP24-L IR region in the LLOV IR wt bicistronic minigenome with a synthesized fragment containing the VP24-L IR with an insertion spanning overlapping LLOV gene start and end signals (GAAGAATATTAAGAAAAA) between nucleotides 138 and 139 of the IR (Twist Biosciences) via NEBuilder HiFi DNA Assembly (New England Biolabs).

Cloning of full-length filovirus plasmids
The LLOV full-length clones were generated by inserting the viral genome sequence in plasmid p15AK in positive sense orientation under the control of the T7 RNA polymerase

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses promoter (S2 Fig). In this plasmid, the leader region is located immediately downstream of the T7 RNA polymerase promoter and the trailer region is flanked by a hepatitis delta (HdV) ribozyme to generate precise viral genome ends. DNA fragments comprising three portions of the full LLOV genome (NC_016144.1) were synthesized as follows. Fragment 1-LE 72 (Twist Biosciences) consisted of a NotI site, a T7 RNA polymerase promoter, nucleotides 1-3 of the EBOV genome, nucleotides 1-4202 of the LLOV genome, a linker sequence to facilitate efficient restriction enzyme digestion (CATCGGGCCCCATC), nucleotides 17160-18927 of the LLOV genome including a single silent mutation within the L ORF (A17164T), nucleotides 18887-18958 of the EBOV genome, ending with a portion of the HdV ribozyme SuperCut II (GGGTCGGCATGGCATCTCCACCTCCTCGCGGTCCG). Fragment 2 (Twist Biosciences) consisted of nucleotides 4197-11536 of the LLOV genome. Fragment 3 (Twist Biosciences) consisted of nucleotides 11531-17165 of the LLOV genome containing the same silent mutation within the L ORF as Fragment 1. DNA fragments comprising a portion of the LLOV L open reading frame (nucleotides 18447-18820) followed by EBOV (nucleotides 18220-18958, EBOV UTR+tr ), or MARV sequences (nucleotides 18477-19111, MARV UTR+tr ) and ending with same portion of the HdV rizbozyme SuperCutII sequence as used in Fragment 1 were synthesized (Twist Biosciences). A DNA portion of Fragment 2 containing an insertion of the ZsGreen-P2A upstream of the VP40 ORF as described previously [10] was synthesized (Twist Biosciences). Finally, a DNA fragment introducing overlapping gene start and end signals into the intergenic region of the VP24-L IR (GAAGAATATTAAGAAAAA between nucleotides 12001 and 12002, IR ins ) was synthesized.
The LLOV-ZsG-IR ins -LE 72 version full-length clone was assembled by first cloning Fragment 1-LE 72 into the p15AK-EBOV plasmid (kind gift of Hideki Ebihara, Mayo Clinic) [44] via NotI and RsrII digestions and ligation. Fragment 3 was then cloned into p15AK-LLOV-Frag1-LE 72 by ApaI and AatII digestions and ligation. Finally, Fragment 2 was cloned into p15AK-LLOV-Frag1-3-LE 72 by XhoI and ApaI digestions and ligation. Other trailer versions of the LLOV full-length clone were assembled by first cloning the LLOV L-EBOV UTR+tr and -MARV UTR+tr fragments into the p15AK-LLOV-Frag1 plasmid via SnaBI and RsrII digestions and ligation. The EBOV UTR+tr and -MARV UTR+tr versions of full-length LLOV clones were assembled by XhoI and AatII digestions and ligation of the backbone portion of the corresponding p15AK-LLOV-Frag1 versions with the Fragment 2+3 portion of the p15AK-L-LOV-LE 72 full length plasmid. ZsGreen-P2A versions of the full-length clone were cloned by first cloning the ZsGreen-P2A fragment into Fragment 2 via XhoI and XmaI digestions and ligation followed by subsequent replacement of this region within the full-length clone via XhoI and ApaI digestions and ligation. IR ins versions of the full-length clone were cloned by first cloning the IR ins fragment into LLOV-Frag3 via ApaI and PciI digestions and ligation followed by subsequent replacement of this region within the full-length clone via ApaI and AatII digestions and ligation.

Monocistronic and bicistronic minigenome transfections
LLOV minigenome transfections were performed as described previously [9]. Briefly, 2x10 5 293T or BHK21 cells were seeded in a 12-well plate one day prior to transfection. The next day, cells were transfected with LLOV minigenome plasmid DNA along with LLOV support plasmids encoding NP, VP35, VP30, and L as well as a plasmid expressing codon-optimized T7 RNA polymerase. As negative controls for LLOV minigenome transfections, pCDNA3.1-mCherry plasmid was used instead of L plasmid. When luciferase-expressing minigenomes were used, plasmid pMIR β-gal expressing β-galactose was co-expressed to normalize against transfection efficiency. Transfection of 293T cells was performed using Tran-sIT-LT1 per manufacturer's recommendations (Mirus Bio LLC).

Virus propagation
EBOV Mayinga and RESTV Pennsylvania virus isolates were kindly provided by the NIH NIAID Rocky Mountain laboratories. EBOV, RESTV, and LLOV stocks were grown in Vero E6 cells and purified using ultracentrifugation through a 20% sucrose cushion as previously described [32]. Virus titers were determined in Vero E6 cells by 50% tissue culture infectious dose (TCID 50 ) assay and calculated using the Spearman-Kärber algorithm. All work with EBOV, RESTV, and LLOV was performed under BSL-4 conditions at the NEIDL, following approved SOPs.

Monocistronic minigenome firefly luciferase assays
At 3 days post-transfection, cell lysates were harvested in Reporter Lysis Buffer (Promega) and analyzed with the Luciferase Assay System (Promega) using a LUMIstar Omega luminometer (BMG LabTech). Cell lysates were diluted in 1x Reporter Lysis Buffer as needed. To account for potential differences in transfection efficiency, luciferase values were normalized to βgalactosidase values (Promega). Luciferase values were then calculated as fold increase over the negative control (minus L) values.

Recombinant Lloviu virus as a tool to study viral replication and host responses
Omega luminometer (BMG LabTech). Cell lysates were diluted in 1x Passive Lysis Buffer as needed. To account for potential differences in transfection efficiency, luciferase values were normalized to β-galactosidase values (Promega). Luciferase values were then calculated as fold induction over the negative control (minus L) values.

Proteomic sample preparation and mass spectrometry analysis
For proteomic analysis, SuBK12-08 cells seeded in 6-well plates (1.5x10 6 cells/well) infected with LLOV-ZsG-IR ins -EBOV UTR+tr at an MOI of 1 were lysed 2 days post-infection. The virus was inactivated by resuspending the cell pellets in roughly 5 packed cell volumes (p.c.v) of GuHCl lysis buffer (6 M guanidine hydrochloride, 100 mM Tris pH 8.0, 40 mM chloroacetamide, 10 mM Tris(2-carboxyethyl)phosphine) supplemented with phosphatase inhibitor cocktail (Roche) followed by heating to 100˚C for 10 minutes. Lysates were removed from the BSL-4 laboratory, sonicated with a Branson probe sonicator and were then quantified via Bradford assay. One hundred sixty micrograms of each sample was diluted with 100 mM Tris buffer, pH 8.5 to decrease the GuHCl concentration to 0.75 M. Lysate proteins were then digested by adding trypsin (Pierce) at a 1:50 ratio (enzyme: protein, w/w) and incubated overnight at 37˚C with shaking. Trypsinization was terminated with the addition of trifluoroacetic acid to below pH 3 and the peptide digests were desalted via reversed-phase C18 columns (Sep-pak, Waters) with a wash buffer of 0.1% TFA and elution buffer of 60% acetonitrile. Peptide concentration was determined by a quantitative colorimetric peptide assay (Thermo Fisher), and 1 μg aliquots of clean peptides from each sample were injected sequentially over a nano-flow C18 column (EasySpray, Thermo Fisher) using a EasyNano LC system coupled to an Orbatrap Exploris mass spectrometer (Thermo Fisher) equipped with FAIMS. Data were gathered in a standard data-dependent manner over a 150-minute gradient.

Analysis of raw mass spectrometry data
All acquired MS/MS spectra were simultaneously searched against both a manually curated database of LLOV proteins based on the reference sequence (GenBank: NC_016144) and the complete reviewed and unreviewed proteome for the common bats family (uniprotKB taxonomy Vespertilionidae [9431], downloaded February 9, 2021) using the MaxQuant software (Version 1.6.7.0) that integrates the Andromeda search engine. Briefly, enzyme specificity was set to trypsin and up to two missed cleavages were allowed. Cysteine carbamidomethylation was specified as fixed modification whereas oxidation of methionine and N-terminal protein acetylation were set as variable modifications. Precursor ions were searched with a maximum mass deviation of 4.5 ppm and fragment ions with a maximum mass deviation of 20 ppm. Peptide and protein identifications were filtered at 1% FDR using the target-decoy database search strategy [45]. Proteins that could not be differentiated based on MS/MS spectra alone were grouped to protein groups (default MaxQuant settings). A threshold Andromeda score of 40 was applied to peptides. The MaxQuant output file designated "proteinGroups" was used for data normalization.

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses tannic acid in water for 30 minutes, washed twice in water and once in 50 mM maleate buffer pH 5.15 (MB) followed by a 30-minute incubation in 1% uranyl acetate in MB. The cells were then washed in MB and water and subsequently dehydrated in grades of alcohol (5 minutes each; 50%, 70%, 95%, 2x 100%). Cells were embedded in plastic by inverting a gelatin capsule filled with Epon/Araldite on top of the coverslip and polymerized at 60˚C for 24 hours. After polymerization, the coverslip was removed by dipping the block in LN 2 .
Ultrathin sections (about 80 nm) were cut on a Reichert Ultracut-S microtome, picked up onto copper grids, stained with lead citrate and examined in a JEOL 1200EX Transmission electron microscope. Images were recorded with an AMT 2k CCD camera.

Transmission electron microscopy and cryoelectron microscopy of filovirus particles
Electron microscopy (EM) and cryo-EM of virion particles were performed as follows. Sucrose cushion-purified stocks of EBOV or LLOV-IR ins -MARV UTR+tr were fixed by adding an equal volume of 20% formalin (Fisher Scientific) for at least 6 hours according to approved inactivation procedures. For negatively stained samples, formalin-fixed EBOV or LLOV (4 μl) was applied to the carbon-coated side of the grid and incubated for 3-5 minutes at room temperature. The grid containing virions was then washed on a 0.1 mL drop of Tris buffer (50 mM Tris, pH 7.6) and blotted briefly using filter paper, two times. Grids were then stained on a 5 μl drop of 1% uranyl acetate, blotted briefly, stained again, blotted, and air dried. For cryo-EM, formalin-fixed Ebola or Lloviu virions (1.8 μl) were applied to Quantifoil 2/2 grids, blotted for 7 seconds, and plunge-frozen in liquid ethane using a Vitrobot Mark III. Transmission EM and cryo-EM were performed on an FEI TF20 EM operated at 160 kV and images were recorded on a TVIPS F416 CMOS camera with a pixel size of 1.68-10.09 Å, using the software SerialEM.

Antiviral drug testing
For small molecule testing, 2x10 4 cells/well of Huh7 and SuBK12-08 cells seeded in 96-well plates were pretreated with the indicated amounts of universal interferon (U-IFN, PBL Assay Science) for 18 hours or remdesivir (Selleck Chemicals Llc), U18666A (Sigma-Aldrich), or DMSO for 30 minutes prior to infection. The cells were then infected with either EBOV-Zs-Green or LLOV-ZsG-IR ins -EBOV UTR+tr at an MOI of 1. Fluorescent and brightfield images of infected cells were taken at 2 days post infection. Quantification of fluorescence was performed by subtracting background fluorescence (average intensity of uninfected cells) from the average fluorescence intensity of individual wells. Samples were performed in triplicate.
Viral neutralization assays using mAb114 [29,46,47] (brand name Ebanga; kindly provided by Nancy Sullivan, NIH NIAID Vaccine Research Center) were performed by pre-treating 2x10 5 TCID 50 units of EBOV-ZsGreen or LLOV-ZsG-IR ins -EBOV UTR+tr with media alone or media containing 200 ng/mL, 2 μg/mL, or 20 μg/mL mAb114 at 37˚C for 1 hour. Following pre-incubation, Huh7 cells were infected with these mixtures, followed by removal of the inocula after 1 hour and replacement with fresh media. Cells were fixed at 2 dpi in 10% formalin (Fisher Scientific) for at least 6 hours. Samples were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI; 200 ng/mL and images covering at least 90% of each well's area at 4x magnification were acquired using a Nikon Ti2 Eclipse microscope and Photometrics Prime BSI camera with NIS Elements AR software. Images were stitched, then imported into QuPath software [48]. Infection rates were determined using the positive cell detection feature in QuPath. Nuclei were detected in the DAPI channel and infected cells were identified by mean fluorescence value in the cytoplasmic region in the green channel.

Recombinant Lloviu virus as a tool to study viral replication and host responses
For cytotoxicity testing, 6x10 4 cells/well of Huh7 and SuBK12-08 cells seeded in 48-well plates were treated with the indicated amounts of universal interferon (U-IFN, PBL Assay Science), remdesivir (Selleck Chemicals Llc), U18666A (Sigma-Aldrich), or DMSO for 2 days. Cell viability was then determined by trypan blue staining using a LUNA-II Automated Cell Counter (Logos Biosystems).

RNA fluorescence in situ hybridization analysis
For RNA fluorescent in situ hybridization (FISH) analysis, MDMs seeded in 8-well chamber slides were mock-infected or infected with the indicated viruses at an MOI of 10. Cells were fixed one day post-infection in 10% formalin for at least 6 hours. RNA FISH was performed using the RNAscope Multiplex Fluorescent V2 kit (Advanced Cell Diagnostics). Filovirus RNA was detected using custom-designed probes (Advanced Cell Diagnostics). Specifically, viral mRNA of each filovirus was detected in channel 1 using probes targeting the VP35 transcripts (Advanced Cell Diagnostics) and stained with Opal 520 fluorophore (Perkin-Elmer). Viral genomic RNA was detected in channel 3 using probes targeting the negative-sense genomic sequences of the NP gene (Advanced Cell Diagnostics) and stained with Opal 690 fluorophore (Perkin-Elmer). All FISH probe sets were designed by Advanced Cell Diagnostics and the sequences of these probe sets are proprietary. Staining was performed according to the manufacturer's protocol for adherent cell samples, with the exception of an additional HRP blocking step following the signal development of the probes detecting viral mRNA as per the manufacturer's recommendation. Nuclei were stained with kit-supplied DAPI following the manufacturer's protocol. Coverslips were mounted on slides using FluorSave mounting medium, and slides were subsequently stored at 4˚C prior to imaging. Images were acquired at 20x magnification from sixteen fields of view per well in two replicate wells of each chamber slide using a Nikon Ti2 Eclipse microscope and Photometrics Prime BSI camera with NIS Elements AR software. Total cell number was determined from images using the QuPath cell detection feature to identify nuclei by DAPI staining, and infected cells were manually identified based on the presence of staining for viral mRNA or genomic RNA.

RNA sample preparation
Total RNA from 2x10 5 (24-well format) MDMs was isolated at one day post-infection using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. RNA concentration was determined by measuring light absorption at a wavelength of 260 nm using a NanoDrop 1000 spectrophotometer (Thermo Fisher).

qRT-PCR analysis
Quantitative reverse transcription-PCR (qRT-PCR) using the QuantiFast SYBR green RT-PCR kit (Qiagen) was performed as described previously [32]. Briefly, five nanograms of mRNA were analyzed by quantitative reverse transcription-PCR (qRT-PCR) using the Quanti-Fast SYBR green RT-PCR kit (Qiagen). qRT-PCR-based quantification of IL-6, IL-8, IFNB, CXCL10, and β2-microglobulin (B2M) mRNAs were performed using validated QuantiTect primer assays (Qiagen). B2M levels were used as an endogenous control for normalization. qRT-PCR was performed in a CFX96 real-time PCR cycler (Bio-Rad). Fold expression levels compared to those of non-infected control samples were quantified using the threshold cycle (ΔΔCT) method (Bio-Rad CFX Manager 1.5 software) for each donor.

PLOS PATHOGENS
Recombinant Lloviu virus as a tool to study viral replication and host responses

Viral RNA sequencing
Total RNA from sucrose cushion-purified viral stocks was isolated using TRIzol-LS reagent (Invitrogen) according to the manufacturer's protocol. RNA concentration was determined using a NanoDrop 1000 spectrophotometer (Thermo Fisher).

RNA-Seq
Sequencing libraries were prepared using the Illumina TruSeq v2 library kit without rRNA depletion or mRNA selection and were sequenced on the Illumina HiSeq 500 to a depth of > 500,000 reads per library. Raw FASTQ files were evaluated for quality using FastQC v0.11.7 [49] followed by alignment to the Vero E6 genome (ChlSab1.1a) using Bowtie2 v2.4.2 [50] with the very-sensitive flag. Reads that did not align to the host genome were passed to Kraken2 v2.0.9 [51] to verify no adventitious agents or other contaminants were present; none were detected. The reads were then aligned to the predicted viral genome using Bowtie2. Viral coverage was assessed with SAMtools v1.10 [52], and single nucleotide variants (SNVs) were called with LoFreq v2.1.3.1 [53]. SNV annotation was performed with Biostrings v2.56.0 [54] and a custom R script.

0 -end genomic sequencing with ViBE-Seq
Viral genomic end sequencing was performed using ViBE-Seq (sequencing of Viral Bonafide Ends), which is a novel method based on the adaptor ligation and cDNA recircularization approaches described previously [55][56][57]. Briefly, 40 ng of RNA was used as a template for reverse transcription with QIAGEN's Sensiscript Reverse Transcription Kit according to the manufacturer's instructions. Specific RT primers were used for cDNA synthesis for each rLLOV-ZsG-IR ins -EBOV UTR+tr (/5Phos/T � A � TGTGAGTCGTATTACCTG/iSp18/GGATCC/ iSp18/CCT TCTTTACAATATAGCAGA) and rLLOV-ZsG-IR ins -MARV UTR+tr (/5Phos/ T � A � TGTGAGTCG TATTACCTG/iSp18/GGATCC/iSp18/GCTGTAATCTACAAGCA CCTCTT), where � denotes a non-scissile phosphorothioate linkage and iSp18 is an 18-atom hexa-ethyleneglycol spacer. Reverse transcription products were run on a 10% denaturing urea polyacrylamide gel for 2 hours at 10 watts. The gel was then stained with SYBR Gold for 10 minutes and gel portions corresponding to 200 nucleotides (rLLOV-ZsG-IR ins -EBOV UTR+tr ) or 230 nucleotides (rLLOV-ZsG-IR ins -MARV UTR+tr ) were excised. The bottom of a 0.2 mL tube was punctured with a 21 gauge needle. Excised gel bands were extruded via centrifugation through the punctured 0.2 mL tube at 21,000 x g for 5 minutes. The pulverized polyacrylamide was resuspended in 0.5 mL of 0.4 M NaCl solution and shaken overnight at 4˚C. Polyacrylamide was eliminated from the slurry via centrifugation through a Spin-X centrifuge tube filter (Costar). cDNA was then precipitated by adding 1 μL of Glycoblue Coprecipitant (Thermo Fisher) and 1 volume of 100% isopropanol, overnight incubation at -20˚C, and centrifugation at 21,000 x g for 1 hour at 4˚C. The pellet was washed with 1 mL of 100% ethanol, allowed to air-dry, and resuspended in 20 μL of nuclease-free water. cDNA was quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher).
Purified cDNA was subject to circularization via CircLigase ssDNA Ligase (Lucigen) per the manufacturer's specifications. Samples were incubated for 2 hours at 60˚C and 10 minutes at 80˚C.
Purified PCR products were submitted for sequencing at Mass General Hospital's Center for Computation and Integrative Biology DNA Core in Cambridge, MA. Data are provided as S1 Dataset.

Statistics
Luciferase assays and drug testing: Standard error of the mean (SEM) and two-tailed t-tests for all figures were calculated using GraphPad Prism software.
Supporting information S1 Fig. Supplementary figure to Fig 1B: Luciferase-based minigenome assays comparing the 3L5E and chimeric 3L5LE X minigenomes with or without L. Mean firefly luciferase activity normalized to ß-galactosidase activity (transfection control) with standard deviation is shown. (TIF)

S2 Fig. Recombinant Lloviu virus (rLLOV comp ) clones used in this study.
Schematics and names of full-length clones of rLLOV comp that were rescued (above) and those that were not (below). Noncoding regions are indicated in light gray, LLOV genes are in gray, a ZsGreen-P2A reporter (ZsG) is in light green followed by a dark gray bar, gene start and end signals are black bars within noncoding regions, red bars indicate the IR ins insertion in the VP24-L intergenic region, dark green indicates the Ebola virus (EBOV) L 3ˈ UTR and trailer (EBOV UTR+tr ), dark blue indicates the Marburg virus L 3ˈ UTR and trailer (MARV UTR+tr ), and pink indicates the last 72 nucleotides of the EBOV trailer (LE 72 ). rLLOV comp clones are to scale with the exception of the T7 RNA polymerase promoter (P T7 ), hepatitis delta virus ribozyme (Rib HdV ), and T7 RNA polymerase terminator sequences (T T7 ) which are enlarged for clarity. Scale bar above indicates 1 kb increments, starting with the first nucleotide of the rLLOV comp clones. Important restriction enzymes that were used to clone full-length rLLOV comp plasmids are indicated above, including an AatII site which introduces a silent mutation within L (A17949T for the rLLOV-ZsG-IR ins -EBOV UTR+tr clone, corresponding to nucleotide 17164 of the published LLOV sequence, NCBI Reference Sequence NC_016144). ins -EBOV UTR+tr sequence and the terminal 230 nucleotides of the rLLOV-ZsG-IR ins -MAR-V UTR+tr sequence. Very few differences were observed between the rLLOV comp full-length clone sequences and the viral stocks (passage 2). Very low abundance differences identified in the rLLOV-ZsG-IR ins -EBOV UTR+tr stock include a deletion (position 20200, found in 0.58% of reads), an A insertion (between nucleotides 20308 and 20309, 0.33% of reads and the cause of the observed large dip in the graph due to its low abundance), a U to A mutation (position 20325, 0.3% of reads), and a U deletion (position 20337, 0.24% of reads) all in distinct, truncated species with very low read abundance. A significant portion of the reads (22.21% of reads) contained a terminal AC dinucleotide which is not present within the corresponding full-length clone. Similar to the data for the rLLOV-ZsG-IR ins -EBOV UTR+tr stock, there are few differences noted between the rLLOV-ZsG-IR ins -MARV UTR+tr sequence and corresponding rLLOV comp full-length clone. The only low abundance difference observed was a single A deletion (position 20309, 2.35% of reads). There were no terminal nucleotide additions present in any of the rLLOV-ZsG-IR ins -MARV UTR+tr sequence reads. (TIF) S8 Fig. Supplementary figure to Fig 5A-5C: Cytotoxicity data from tested antiviral compounds. Huh7 and SuBK12-08 cells were treated as indicated for 2 days and cell viability was determined by trypan blue staining. (TIF) S9 Fig. Supplementary figure to Fig 6: Uninfected mock controls for the RNA FISH data shown in Fig 6. Human monocyte-derived macrophages (MDMs) were left uninfected, fixed at 1 dpi, and analyzed for the presence of negative (genome, magenta, in top row) and positive (mRNA and antigenome, green, in middle row) sense viral RNA using the indicated probe sets by RNA FISH. Cells were co-stained with DAPI (shown with merged channels, in bottom row). Indicated size bar is the same for all images. (TIF) S10 Fig. Supplementary figure to Fig 6: RNA FISH analysis of human monocyte-derived macrophages (MDMs) infected with EBOV, RESTV, or rLLOV. MDMs derived from donor 1 were infected at an MOI of 10 with EBOV, RESTV, or rLLOV-IR ins -MARV UTR+tr . At 1 dpi, cells were fixed and analyzed for the presence of negative (genome, magenta, in top row) and positive (mRNA and antigenome, green, in middle row) sense viral RNA by RNA FISH. Cells were co-stained with DAPI (shown with merged channels, in bottom row). Images are shown with increased brightness in green and magenta channels to clearly visualize lower-intensity staining observed in rLLOV-IR ins -MARV UTR+tr -infected cells. Indicated size bar is the same for all images. (TIF) S1 Dataset. Viral genome end sequence data was derived from plain text files generated from CRISPR amplicon Next-generation sequencing. The attached files contain a list of unique sequence contigs synthesized from the overlap of two reads (forward and reverse) generated during the sequencing process. The list contains the contigs in order from highest abundance to lowest abundance in the samples provided. Furthermore, each unique contig comes with the number of pairs of NGS reads which make up each contig. This sequencing was performed on gel-extracted dsDNA PCR products by the Mass General Hospital Center for Computational and Integrative Biology (CCIB) DNA Core.